Severe RSV disease remains a serious threat

Recent studies show a trend in increased RSV hospitalizations and complications among high-risk infants1-4

SENTINEL1 study:

A study of preterm infants 29-35 wGA hospitalized with laboratory-confirmed RSV during the 2014-2015 and 2015-2016 RSV seasons1

McLaurin et al study:

A study of 2014-2015 RSV hospitalization rates in commercially insured and Medicaid preterm infants compared with the previous 4 seasons2,3

Friedman et al study:

A 2016 study of RSV hospitalization, mechanical ventilation, and inpatient mortality among children with specific CHD diagnoses during their second year of life4


Experts discuss findings of SENTINEL1 and McLaurin et al studies


Learning more about the consequences of severe RSV disease for high-risk patients and their families


  1. DeVincenzo J, Anderson E, Checchia P, et al. SENTINEL1: A Multicenter Observational Study of Respiratory Syncytial Virus Hospitalizations Among US Infants Born at 29–35 Weeks’ Gestational Age Not Receiving Immunoprophylaxis in 2014–2016. Presented at: Pediatric Academic Societies (PAS) Annual Meeting; May 6-9, 2017; San Francisco, CA.
  2. McLaurin K, Pavilack M, Krilov L, et al; [poster #123892]. Presented at: Academy of Managed Care Pharmacy Nexus, National Harbor, MD, October 3-6, 2016.
  3. Data on file, 3336710, AstraZeneca Pharmaceuticals LP.
  4. Friedman D, Fryzek J, Jiang X, Bloomfield A, Ambrose CS, Wong PC. Respiratory syncytial virus hospitalization risk in the second year of life by specific congenital heart disease diagnoses. PLoS ONE. 12(3): e0172512. doi:10.1371/ journal.pone.0172512.